Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

September 23, 2020

View Press Release Corporate presentation Contact us
Previous